{"id":37150,"date":"2025-07-11T11:43:01","date_gmt":"2025-07-11T03:43:01","guid":{"rendered":"https:\/\/flcube.com\/?p=37150"},"modified":"2025-07-11T11:43:02","modified_gmt":"2025-07-11T03:43:02","slug":"allists-furmonertinib-granted-priority-review-for-egfr-exon-20-nsclc-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37150","title":{"rendered":"Allist&#8217;s Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China"},"content":{"rendered":"\n<p>Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/688578:SHA\">SHA: 688578<\/a>) announced that its Category 1 small molecule targeted drug, furmonertinib, has been granted priority review status by China&#8217;s Center for Drug Evaluation (CDE). The drug is being evaluated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with EGFR exon 20 insertion mutations (exon20ins) who have progressed on or are intolerant to platinum-based chemotherapy.<\/p>\n\n\n\n<p><strong>Furmonertinib&#8217;s Clinical Progress<\/strong><br>Previously, furmonertinib had already received Breakthrough Therapy Designation (BTD) from the CDE for its second-line treatment of EGFR exon20ins NSCLC. The drug represents a significant advancement in the treatment landscape for this specific patient population, offering new hope where limited options previously existed.<\/p>\n\n\n\n<p><strong>Drug Profile and Development<\/strong><br>Furmonertinib is an internally discovered, irreversible, selective third-generation EGFR tyrosine-kinase inhibitor. Allist is co-developing the drug in territories outside of Greater China with ArriVent under a 2021 agreement. The drug was first approved in China in March 2021 for treating patients with locally advanced or metastatic NSCLC that is EGFR T790M mutation-positive and has progressed following treatment with an earlier generation EGFR-targeted TKI. It subsequently received approval for use in first-line locally advanced or metastatic NSCLC with EGFR exon 19 deletion or exon 21 (L858R) replacement mutation in June 2022. Both indications are covered by the National Reimbursement Drug List (NRDL).<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/688578_20250710_PCBN.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688578_20250710_PCBN.\"><\/object><a id=\"wp-block-file--media-97c30de0-6116-46ba-834a-95cb6ccda185\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/688578_20250710_PCBN.pdf\">688578_20250710_PCBN<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/688578_20250710_PCBN.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-97c30de0-6116-46ba-834a-95cb6ccda185\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that its Category 1 small molecule&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37154,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[138,16,80,922,33],"class_list":["post-37150","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-allist-pharmaceuticals","tag-cancer","tag-priority-reviews","tag-sha-688578","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Allist&#039;s Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that its Category 1 small molecule targeted drug, furmonertinib, has been granted priority review status by China&#039;s Center for Drug Evaluation (CDE). The drug is being evaluated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with EGFR exon 20 insertion mutations (exon20ins) who have progressed on or are intolerant to platinum-based chemotherapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37150\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allist&#039;s Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China\" \/>\n<meta property=\"og:description\" content=\"Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that its Category 1 small molecule targeted drug, furmonertinib, has been granted priority review status by China&#039;s Center for Drug Evaluation (CDE). The drug is being evaluated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with EGFR exon 20 insertion mutations (exon20ins) who have progressed on or are intolerant to platinum-based chemotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37150\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-11T03:43:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-11T03:43:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1103.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37150#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37150\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Allist&#8217;s Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China\",\"datePublished\":\"2025-07-11T03:43:01+00:00\",\"dateModified\":\"2025-07-11T03:43:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37150\"},\"wordCount\":236,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37150#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1103.webp\",\"keywords\":[\"Allist Pharmaceuticals\",\"Cancer\",\"Priority reviews\",\"SHA: 688578\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37150#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37150\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37150\",\"name\":\"Allist's Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37150#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37150#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1103.webp\",\"datePublished\":\"2025-07-11T03:43:01+00:00\",\"dateModified\":\"2025-07-11T03:43:02+00:00\",\"description\":\"Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that its Category 1 small molecule targeted drug, furmonertinib, has been granted priority review status by China's Center for Drug Evaluation (CDE). The drug is being evaluated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with EGFR exon 20 insertion mutations (exon20ins) who have progressed on or are intolerant to platinum-based chemotherapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37150#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37150\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37150#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1103.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1103.webp\",\"width\":1080,\"height\":608,\"caption\":\"Allist's Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37150#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allist&#8217;s Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Allist's Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that its Category 1 small molecule targeted drug, furmonertinib, has been granted priority review status by China's Center for Drug Evaluation (CDE). The drug is being evaluated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with EGFR exon 20 insertion mutations (exon20ins) who have progressed on or are intolerant to platinum-based chemotherapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37150","og_locale":"en_US","og_type":"article","og_title":"Allist's Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China","og_description":"Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that its Category 1 small molecule targeted drug, furmonertinib, has been granted priority review status by China's Center for Drug Evaluation (CDE). The drug is being evaluated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with EGFR exon 20 insertion mutations (exon20ins) who have progressed on or are intolerant to platinum-based chemotherapy.","og_url":"https:\/\/flcube.com\/?p=37150","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-11T03:43:01+00:00","article_modified_time":"2025-07-11T03:43:02+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1103.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37150#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37150"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Allist&#8217;s Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China","datePublished":"2025-07-11T03:43:01+00:00","dateModified":"2025-07-11T03:43:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37150"},"wordCount":236,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37150#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1103.webp","keywords":["Allist Pharmaceuticals","Cancer","Priority reviews","SHA: 688578","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37150#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37150","url":"https:\/\/flcube.com\/?p=37150","name":"Allist's Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37150#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37150#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1103.webp","datePublished":"2025-07-11T03:43:01+00:00","dateModified":"2025-07-11T03:43:02+00:00","description":"Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that its Category 1 small molecule targeted drug, furmonertinib, has been granted priority review status by China's Center for Drug Evaluation (CDE). The drug is being evaluated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with EGFR exon 20 insertion mutations (exon20ins) who have progressed on or are intolerant to platinum-based chemotherapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37150#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37150"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37150#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1103.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1103.webp","width":1080,"height":608,"caption":"Allist's Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37150#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Allist&#8217;s Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1103.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37150"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37150\/revisions"}],"predecessor-version":[{"id":37155,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37150\/revisions\/37155"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37154"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}